Matthew K. Fust - 26 Jul 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Director
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 26 Jul 2021
Net transactions value: -$88,400
Form type: 4
Filing time: 27 Jul 2021, 20:00:21 UTC
Previous filing: 20 Jul 2021
Next filing: 09 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$9,550	+5,000	+40%	$1.91^*	17,536	26 Jul 2021	Direct	F1
transaction	CRNX	Common Stock	Sale	$97,950	-5,000	-29%	$19.59	12,536	26 Jul 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Non-qualified stock option (Right to Buy)	Options Exercise	$0	-5,000	-16%	$0.000000	27,092	26 Jul 2021	Common stock	5,000	$1.91	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2	Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.
F3	The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.